Dugel Pravin sold $173K of OCUL

Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results. Revenue was $13.48 million, flat year over year, but 5.3% above Wall Street estimates. GAAP EPS was -$0.35, 11.2% better than consensus. The company said its June Investor Day outlined an FDA-aligned NDA submission path for AXPAXLI for wet AMD in Q4 2026. Shares rose 1.2% to $8.27.

Ocular Therapeutix (OCUL) reported Q2 results for the period ended June 30: GAAP EPS of -$0.35 on revenue of $13.48M, both beating Wall Street expectations. The company said its AXPAXLI wet AMD NDA path is planned for Q4 2026 via FDA 505(b)(2), using SOL-1 data plus SOL-R interim safety. Cash was $598.6M.

OCULAR THERAPEUTIX, INC (OCUL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621618d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA

Ocular Therapeutix (OCUL) told the H.C. Wainwright ophthalmology conference that the FDA has formally aligned on a complete submission package for AXPAXLI under a single-trial pathway for wet age-related macular degeneration. The company cited SOL-1 results, including a P value below 0.0006, and said it had $667 million cash at Q1 end.

Ocular Therapeutix said it plans to submit an NDA for AXPAXLI in wet AMD in Q4 2026 after aligning with the FDA on a strategy based on SOL-1 efficacy/safety plus interim SOL-R safety data. The FDA will review the application using SOL-1 only; SOL-1 met its primary endpoint (p=0.0006). SOL-R was redesigned, with topline data expected in Q1 2028. The company also prioritized HELIOS-3 for diabetic retinopathy. Shares were up 6.49% to $9.52.

Acuta Capital sold 56% of its Ocular Therapeutix shares in Q1, according to the article. It also notes investors may want to monitor Ocular Therapeutix’s investor day on June 17 for further updates. No specific financial figures or price impacts were provided.